Treatment of childhood astrocytomas with irinotecan and cisplatin
Clin. transl. oncol. (Print)
; 20(4): 500-507, abr. 2018. tab, graf
Article
em En
| IBECS
| ID: ibc-171643
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Background. Previously we described the outcome of children with spinal cord astrocytoma treated with irinotecan and cisplatin (I/C). We here report the review of the initial institutional experience using this combination for children with low-grade glioma (LGG). Procedure. I/C chemotherapy consisted of weekly cisplatin (30 mg/m2) and irinotecan (50-65 mg/m2) for a total maximum of 16 doses, administered in an outpatient basis. Results. Between November 2002 and December 2009, 46 children (median age 6.3 years; range 0.3-17.7) with glioma were treated. We here report the cohort of 31 patients with LGG. Patients received a median of 16 cycles of I/C (range 8-16). The overall objective response [complete response (CR) + partial response (PR)] and disease control (CR + PR + stable disease) rates to I/C treatment were 6.5% [95% confidence interval (CI), 0.8-21.4%] and 93.5% (95% CI 78.6-99.2%), respectively. Disease control persisted for a median of 65 months. Toxicity was predominantly myelosuppression only seen in heavily pretreated patients. Survival analysis shows 5-year event-free survival (EFS) of 54% and 5-year overall survival (OS) of 80%. Conclusion. I/C chemotherapy produced disease control and clinical improvement in a majority of children with low-grade glioma, with manageable toxicity (AU)
RESUMEN
No disponible
Buscar no Google
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Astrocitoma
/
Neoplasias da Medula Espinal
/
Cisplatino
Limite:
Child
/
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Article